BioCentury | Nov 7, 2019
Product Development

AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation. As...
BC Week In Review | Dec 21, 2018
Company News

Furen gets rights to AZD0364 from AstraZeneca

Shanghai Furen Medicine R&D Co. Ltd. (Shanghai, China) gained Chinese rights to cancer candidate AZD0364 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Shanghai Furen is a subsidiary of Furen Medicines Group Co. Ltd. (Zhengzhou, China). AZD0364 is...
Items per page:
1 - 2 of 2